NIHR MHRN and Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK.
BMC Psychiatry. 2013 Jan 15;13:28. doi: 10.1186/1471-244X-13-28.
Long acting injections (LAI) have been associated with perceptions of coercion in cross sectional studies but there have been no longitudinal studies of the effects on clinical relationships with newer depot medications.
Randomized controlled trial with (50) participants with a diagnosis of schizophrenia randomized to risperidone LAI or oral atypical antipsychotic medication. The main outcome was the Working Alliance Inventory (WAI) with background variables (symptoms, side effect, social functioning, quality of life) measured before randomization and at two years.
At follow-up (14 risperidone LAI and 16 oral medication) analyses including predictors of missing data and baseline score showed a trend for those on risperidone LAI to reduce WAI score and those on oral medication showing no change. Sensitivity analyses showed (i) a significant detrimental effect of LAI on WAI and (ii) the pattern of results was not affected by change in symptoms over the study.
This is the first study to show that the prescription of depot atypical depot medication is associated with detrimental effects on clinical relationships after 2 years of continual treatment.
长效注射剂（LAI）在横断面研究中与强制感相关，但对于新型储库药物对临床关系的影响，尚无纵向研究。
一项随机对照试验，共 50 名诊断为精神分裂症的患者随机分配至利培酮 LAI 或口服非典型抗精神病药物。主要结局指标是工作联盟量表（WAI），背景变量（症状、副作用、社会功能、生活质量）在随机分组前和两年时进行测量。
在随访时（14 名接受利培酮 LAI 治疗，16 名接受口服药物治疗），包括缺失数据和基线评分的预测因素分析显示，接受利培酮 LAI 治疗的患者 WAI 评分呈下降趋势，而接受口服药物治疗的患者则无变化。敏感性分析显示（i）LAI 对 WAI 有显著的不良影响，（ii）研究期间症状变化对结果模式没有影响。
这是第一项研究表明，在持续治疗 2 年后，储库型非典型储库药物的处方与临床关系的不良影响有关。
